Arylamine N-acetyltransferase activity in man
Arylamine N-acetyltransferase activity in man
复制标题
DOI：
10.1081/dmr-100101932
复制
发表时间：
1999-01-01
影响因子：
5.9
通讯作者：
Roots, I
中科院分区：
文献类型：
--
作者：
Cascorbi, I;Brockmöller, J;Roots, I
肝芳胺n -乙酰转移酶2 （NAT2）是最常见的表型多态性药物代谢酶之一。人n -乙酰转移酶NAT1和NAT2是伯胺和肼代谢途径中的主要酶。除了某些药物，如异烟肼、氨苯砜和肼嗪（表1）外，它们还通过n -和/或o -乙酰化[1]代谢其他含有芳香胺的外源药物。对导致慢速和快速乙酰化个体的遗传多态性的观察，使人们的兴趣集中在它们调节某些恶性肿瘤和其他疾病风险的作用上，但也集中在药物副作用的风险上。
Hepatic arylamine N-acetyltransferase 2 (NAT2) is one of most frequently phenotyped polymorphic drug-metabolizing enzymes. Both human N-acetyltransferases, NAT1 and NAT2, act as major enzymes in the metabolic pathway of primary amines and hydrazines. Beside certain drugs such as isoniazid, dapsone, and hydralazine (Table 1), they metabolize other xenobiotics containing aromatic amines by N-and/or O-acetylation [1]. The observation of hereditary polymorphisms resulting in slow-and rapid-acetylator individuals has focused the interest on their role to modulate risk of certain malignancies and other diseases, but also to the risk of drug side effects [2].